Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Oct;34(5):608-12.
doi: 10.1097/JCP.0000000000000192.

A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept

Cenk Tek  1 , Joseph Ratliff, Erin Reutenauer, Rohan Ganguli, Stephanie S O'Malley
Affiliations
Randomized Controlled Trial

A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept

Cenk Tek et al. J Clin Psychopharmacol. 2014 Oct.

Abstract

Patients with schizophrenia experience higher rates of obesity as well as related morbidity and mortality than the general population does. Women with schizophrenia are at particular risk for antipsychotic-associated weight gain, obesity, and related medical disorders such as diabetes and cardiovascular disease. Given preclinical studies revealing the role of the endogenous opioid systems in human appetite and the potential of antipsychotic medications to interfere with this system, we hypothesized that opioid antagonists may be beneficial in arresting antipsychotic-associated weight gain and promoting further weight loss in women with schizophrenia. In the present study, 24 overweight women with a diagnosis of schizophrenia or schizoaffective disorder were randomized to placebo or naltrexone (NTX) 25 mg/d for 8 weeks. The primary outcome measure was a change in body weight from baseline. The patients in the NTX group had significant weight loss (-3.40 kg) compared with weight gain (+1.37 kg) in the patients in the placebo group. Mainly, nondiabetic subjects lost weight in the NTX arm. These data support the need to further investigate the role of D2 blockade in reducing food reward-based overeating. A larger study addressing the weaknesses of this pilot study is currently underway.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Weight Change (Mean kg ± SE) for Diabetic (DM) and Non-Diabetic (Non-DM) subjects on naltrexone (NTX) and Placebo (Pla)
See this image and copyright information in PMC

References

    1. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiat. 1999;60:215–220. - PubMed
    1. Saari KM, Lindeman SM, Viilo KM, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. The Journal of clinical psychiatry. 2005;66:559–563. - PubMed
    1. Phutane VH, Tek C, Chwastiak L, et al. Cardiovascular risk in a first-episode psychosis sample: a ‘critical period’ for prevention? Schizophrenia research. 2011;127:257–261. - PMC - PubMed
    1. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA: the journal of the American Medical Association. 2007;298:1794–1796. - PubMed
    1. Barber JA, Palmese L, Reutenauer EL, et al. Implications of weight-based stigma and self-bias on quality of life among individuals with schizophrenia. J Nerv Ment Dis. 2011;199:431–435. - PMC - PubMed

Publication types

MeSH terms